MB RESEARCH LABORATORIES, INC.

Biotech · Private

ELDAC (Egg LD50 Assay for Categorization)—an in vitro egg-based toxicity assay to replace mammalian LD50 testing for acute oral toxicity classification

Grants
$1.9M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Evaluating Photogenotoxicity using 3D Tissue Models$133,124
Federal grantDepartment of Health and Human Services · Phase II · Integrated In Vitro and Alternative Ocular (IIVAO) Irritation Testing Strategy$224,943
Federal grantDepartment of Health and Human Services · Phase II · Integrated In Vitro and Alternative Ocular (IIVAO) Irritation Testing Strategy$635,245
Federal grantDepartment of Health and Human Services · Phase II · Integrated In Vitro and Alternative Ocular (IIVAO) Irritation Testing Strategy$636,469
Federal grantDepartment of Health and Human Services · Phase I · Egg LD50 Assay for Categorization$259,274
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1733Iterum Therapeutics plc—$127M
1734Jnana Therapeutics—$110M
1735STRYKAGEN CORPORATION——
1736MB RESEARCH LABORATORIES, INC.——
1737EpimedX, LLC——
1738Alpha Cognition Inc.—$28M
1739Opprtna Therapeutics, Inc.—$125K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.